Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled Syringe or Auto Injector in Patients With Systemic Lupus Erythematosus

Trial Profile

Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled Syringe or Auto Injector in Patients With Systemic Lupus Erythematosus

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 May 2016

At a glance

  • Drugs Tabalumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Pharmacokinetics; Registrational
  • Sponsors Eli Lilly
  • Most Recent Events

    • 08 Apr 2016 Status changed from completed to discontinued.
    • 06 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 25 Nov 2014 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top